Article Details
Retrieved on: 2024-01-09 18:10:36
Tags for this article:
Click the tags to see associated articles and topics
Excerpt
Eylea sales have been under pressure in 2023 due to competition from Roche's RHHBY Vabysmo. The uptake of Vabysmo has been outstanding. RHHBY ...
Article found on: finance.yahoo.com
This article is found inside other hiswai user's workspaces. To start your own collection, sign up for free.
Sign UpAlready have an account? Log in here